epidermal-growth-factor and Hemorrhage

epidermal-growth-factor has been researched along with Hemorrhage* in 5 studies

Other Studies

5 other study(ies) available for epidermal-growth-factor and Hemorrhage

ArticleYear
Intravesical Instillation of Kangfuxin Liquid Combined with Thrombin and Epidermal Growth Factor for Radiation-induced Hemorrhagic Cystitis in Patients with Cervical Cancer: A report of 34 cases.
    Bioengineered, 2021, Volume: 12, Issue:1

    This study aimed to assess the effectiveness and safety of intravesical instillation treatment of Kangfuxin liquid (KFL) combined with thrombin and epidermal growth factor (EGF) for radiation-induced hemorrhagic cystitis (HC) in patients with cervical cancer. A total of 34 patients with radiation-induced HC of grade 2-4 were treated with intravesical instillation of KFL combined with thrombin and EGF until the complete disappearance of hematuria and lower urinary tract symptoms (LUTS). Gentamicin was added if white blood cells were detected and bacterial culture was positive in the urine. All patients were followed up for 2 years to evaluate the clinical efficacy and safety of the treatment regimen. Patients with and without recurrent hematuria (n = 3, 9% and n = 31, 91%, respectively) were completely recovered from hematuria and LUTS by intravesical instillation treatment for 6-22 days. No adverse event was reported during the treatment and the 2-year follow-up for all patients. Thus, intravesical instillation of KFL combined with thrombin and EGF is an effective and safe therapeutic regimen for radiation-induced HC of grade 2-4 in patients with cervical cancer.

    Topics: Administration, Intravesical; Adult; Aged; Cystitis; Epidermal Growth Factor; Female; Hemorrhage; Hemostatics; Humans; Materia Medica; Middle Aged; Radiation Injuries; Radiotherapy; Thrombin; Uterine Cervical Neoplasms

2021
Hemostatic action of EGF-endospray on mucosectomy-induced ulcer bleeding animal models.
    Bio-medical materials and engineering, 2015, Volume: 25, Issue:1

    Gastric bleeding is one of the irritant problems in ulcer patients. In this study, we evaluated hemostatic action of ulcer-coating powder (EGF-endospray) on gastric ulcer animal models. EGF-endospray, containing epidermal growth factor, is designed to be applied through an endoscope. Hemostatic action of the EGF-endospray was evaluated on gastric hemorrhage models of rabbits and micro-pigs. The EGF-endospray was directly applied onto a mucosal resection (MR)-induced gastric bleeding focus in a rabbit model. In a porcine model, the EGF-endospray was applied once via an endoscopy to a bleeding lesion created by endoscopic submucosal dissection. The bleeding focus was then observed via an endoscope. In the rabbit model, EGF-endospray treatment significantly shortened mean bleeding time in comparison with other treatments (104.3 vs 548.0 vs 393.2 s for the EGF-endospray, the non-treated control and the epinephrine injection, respectively). In the micro-pig model, EGF-endospray showed immediate hemostatic action and prolonged covering of the bleeding focus for over 72 h. Histology proved mucosal thickness was more efficiently recovered in all EGF-endospray treated animals. The results of the present study suggest that the EGF-endospray is a promising hemostatic agent for GI bleeding.

    Topics: Animals; Cell Proliferation; Disease Models, Animal; Epidermal Growth Factor; Female; Gastric Mucosa; Hemorrhage; Hemostasis; Hemostatics; Hydrogels; Models, Animal; Mucous Membrane; Powders; Rabbits; Stomach Ulcer; Swine; Swine, Miniature

2015
A point mutation in the EGF-4 domain of β(3) integrin is responsible for the formation of the Sec(a) platelet alloantigen and affects receptor function.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:1

    Neonatal alloimmune thrombocytopenia (NAIT) is caused by fetomaternal platelet incompatibility with maternal antibodies crossing the placenta and destroying fetal platelets. Antibodies against human platelet antigen-1a (HPA-1a) and HPA-5b are responsible for the majority of NAIT cases. We observed a suspected NAIT in a newborn with a platelet count of 25 G/l and petechial haemorrhages. Serological analysis of maternal serum revealed an immunisation against αIIbβ3 on paternal platelets only, indicating the presence of an antibody against a new rare alloantigen (Sec(a)) residing on αIIbβ3. The location of Sec(a) on αIIbβ3 was confirmed by immunoprecipitation. Nucleotide sequence analysis of paternal β3 revealed a single nucleotide exchange (G(1818)T) in exon 11 of the β3 gene (ITGB3), changing Lys(580) (wild-type) to Asn(580) (Sec(a)). Two additional members of the family Sec were typed Sec(a) positive, but none of 300 blood donors. Chinese hamster ovary cells expressing Asn(580), but not Lys(580) αIIbβ3, bound anti-Sec(a), which was corroborated by immunoprecipitation. Adhesion of transfected cells onto immobilised fibrinogen showed reduced binding of the Asn(580) variant compared to wild-type αIIbβ3. Analysis of transfected cells with anti-LIBS and PAC-1 antibody showed reduced binding when compared to the wild-type. No such effects were observed with Sec(a) positive platelets, which, however, are heterozygous for the Lys(580)Asn mutation. In this study, we describe a NAIT case caused by maternal alloimmunisation against a new antigen on αIIbβ3. Analysis with mutant transfected cells showed that the Lys(580)Asn mutation responsible for the formation of the Sec(a) antigenic determinant affects αIIbβ3 receptor function.

    Topics: Adult; Animals; Blood Platelets; CD18 Antigens; CHO Cells; Cricetinae; Epidermal Growth Factor; Female; Fetus; Fibrinogen; Genotype; Hemorrhage; Heterozygote; Humans; Infant, Newborn; Integrin beta3; Isoantibodies; Isoantigens; Platelet Adhesiveness; Platelet Membrane Glycoprotein IIb; Point Mutation; Pregnancy; Pregnancy Complications; Sequence Analysis, DNA; Transfection

2012
Successful application of epidermal growth factor for treatment of hemorrhagic cystitis after bone marrow transplantation.
    Bone marrow transplantation, 2003, Volume: 31, Issue:7

    Topics: Adolescent; Bone Marrow Transplantation; Cystitis; Epidermal Growth Factor; Hemorrhage; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male

2003
Histopathological and immunohistochemical studies on arteritis induced by fenoldopam, a vasodilator, in rats.
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2001, Volume: 53, Issue:1

    Fenoldopam, a dopaminergic (DA1) agonist, has been reported to induce medial necrosis and adventitial inflammatory response in the splanchnic arteries in rats. This study was carried out to clarify the detailed time course of the inflammatory responses, using antibodies for the inflammatory cell markers, CD3 (T cell), CD20 (B cell) and ED-1 (macrophage), and inflammatory serum factors, IgG, IgM and C3. Rats were administered fenoldopam for 24 hours by intravenous infusion. Histopathologically, medial necrosis with hemorrhage was observed at the end of infusion, but it almost disappeared on day 7 post-infusion. Adventitial inflammatory responses with ED-1-, CD3- and CD20-positive cells were very slight at the end of infusion, became prominent with marked fibrosis on days 3 and 5, decreased on day 7, and subsided on day 14. The serum factors were first present in the area of medial necrosis, then shifted to the subendothelial space or cytoplasm of smooth muscle cells, and disappeared on day 14 post-infusion. Gaps in the external elastic lamina were observed on days 3 and 5 post-infusion, and IgG and IgM were present outside the gaps in the adventitia. These results provided us with more detailed information on the inflammatory responses following medial damage induced by vasodilators.

    Topics: Animals; Antigens, CD20; Arteritis; Biomarkers; CD3 Complex; Epidermal Growth Factor; Fenoldopam; Fluorescent Antibody Technique, Indirect; Hemorrhage; Heparin-binding EGF-like Growth Factor; Immunoenzyme Techniques; Immunoglobulin G; Immunoglobulin M; Infusions, Intravenous; Intercellular Signaling Peptides and Proteins; Male; Rats; Rats, Inbred F344; Time Factors; Tunica Media; Vasodilator Agents

2001